Trial Profile
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results (n=541) of a secondary post-hoc analysis of SWOG Studies S0777 and S1211 assessing impact of Dexamethasone dose reductions on post-induction outcomes in subset of patients who completed all eight 3-week cycles of induction presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 07 Jun 2022 Primary endpoint has not been met (Progression-free Survival), as per Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology